John Keilty

Folks, right now, 25 of the largest pharmaceutical companies in America control 70% of the market. This lack of competition drives up prices – making it harder for hardworking American families to access the health care they need. Today, my Administration is doing something about it. Let me explain: Hundreds of billions of taxpayer dollars are spent on research, discovery, and development of new prescription drugs. And while I firmly believe that the strength of a nation can be measured by the boldness of its science, the quality of its research, and the progress it helps bring forth, I also believe that the folks who paid for the research – you – ought to be able to access and afford the final product. That's why my Administration is proposing that if a drug made using taxpayer funds is not reasonably available to Americans, the government reserves the right to "march in" and license that drug to another manufacturer who could sell it for less. This is an important step toward ending Big Pharma price gouging. It's good for competition. It's good for our economy. And it's good for the millions of Americans who can't afford their medications – who know all too well that fine line between dignity and dependence that the price of a prescription drug can draw.

“March In” rights are the most absurd proposal for drug price controls by progressive left & populist right. Most NIH IP covers a sliver of a product IP. Granting sliver to Generic Co does not create FTO and Generic Co still needs to manufacture & develop the product (5+ yrs).

Please join us in welcoming Mary Lynne Hedley to TRV as our newest Venture Partner. She brings valuable leadership and strategic insight across R&D, operations, corporate strategy and business development. We are excited to have her as part of the team!